We have conducted a comprehensive survey of copy number alterations in HER2+ breast tumors using a combination of aCGH and gene expression analysis, pinpointing significant genomic alterations including both known and potentially novel therapeutic targets. The gene discussed is ERBB2; the disease is breast neoplasm.